参考文献
(在框内滑动手指即可浏览)
[1] 张斌. 乳腺癌综合治疗的新概念[J]. 中国实用外科杂志, 2003, 23(10): 578-580.
[2] Liu M ,Wang CB,Xie F, et al. Clinical practice guidelines for diagnosis and treatment of invasive breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021[J]. Chin Med J (Engl),2021,134(9):1009-1013.
[3] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis, Version 1. 2020[EB/OL].(2020-09-17)[2021-01-25]. https://www. nccn. org/professionals/physician_gls/pdf/breast. pdf.
[4] Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review [J]. JAMA, 2015, 314 (15): 1615-1634.
[5] Shapiro S. Periodic screening for breast cancer: the HIP randomized controlled trial [J]. J Natl Cancer Inst Monogr, 1997 (22): 27-30.
[6] Tabár L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up [J]. Radiol Clin North Am, 2000, 38 (4): 625-651.
[7] Sood R, Rositch AF, Shakoor D, et al. Ultrasound for breast cancer detection globally: a systematic review and meta-analysis [J]. J Glob Oncol, 2019, 5: 1-17.
[8] Ohuchi N, Suzuki A, Sobue T, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial [J]. Lancet, 2016, 387 (10016): 341-348.
[9] Shen S, Zhou Y, Xu Y, et al. A multi-centre randomised trial comparing ultrasound vs mammography for screening breast cancer in high-risk Chinese women [J]. Br J Cancer, 2015, 112 (6): 998-1004.
[10] 许娟, 王颀, 马宏民, 等. 体检联合超声补充X射线钼靶检查乳腺癌筛查模式初步应用评价 [J]. 中华肿瘤防治杂志, 2013, 20 (17): 1295-1299.
[11] Lord SJ, Lei W, Craft P, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer [J]. Eur J Cancer, 2007, 43 (13): 1905-1917.
[12] Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography [J]. CA Cancer J Clin, 2007, 57 (2): 75-89.
[13] Wang F, Duan XN, Ling R, et al. Clinical practice guidelines for risk assessment to identify women at high risk of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021[J]. Chin Med J (Engl),2021,134(14):1655-1657.
[14] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer, version 6. 2020 [EB/OL].(2020-09-08)[2021-02-25]. https://www. nccn. org/professionals/physician_gls/pdf/breast. pdf.
[15] Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer [J]. J Clin Oncol, 2008, 26 (19): 3248-3258.
[16] De Bresser J, De Vos B, Van der ent F, et al. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review [J]. Eur J Surg Oncol, 2010, 36 (2): 114-119.
[17] Debald M, Abramian A, Nemes L, et al. Who may benefit from preoperative breast MRI?A single-center analysis of 1102 consecutive patients with primary breast cancer [J]. Breast Cancer Res Treat, 2015, 153 (3): 531-537.
[18] Marinovich ML, Macaskill P, Irwig L, et al. Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis [J]. BMC Cancer, 2015, 15: 662.
[19] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范 (2019年版)[J]. 中国癌症杂志, 2019, 29 (8): 609-680.
[20] Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894[J]. Ann Surg,1894,20(5):497-555.
[21] Patey DH, Dyson WH. The prognosis of carcinoma of the breast in relation to the type of operation performed[J]. Br J Cancer,1948,2(1): 7-13
[22] Auchincloss H. Significance of location and number of axillary metastases in carcinoma of the breast [J]. Ann Surg, 1963, 158 (1): 37-46.
[23] Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clin- ical trial comparing total mastectomy and segmental mastectomy with or with- out radiation in the treatment of breast cancer [J]. N Engl J Med,1985,312(11):665-673.
[24] Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer [J]. N Engl J Med, 2002, 347 (16): 1233-1241.
[25] Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial [J]. Lancet Oncol, 2010, 11 (10): 927-933.
[26] Lanitis S, Tekkis PP, Sgourakis G, et al. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies [J]. Ann Surg, 2010, 251 (4): 632-639.
[27] De La Cruz L, Moody AM, Tappy EE, et al. Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-
analysis and systematic review [J]. Ann Surg Oncol, 2015, 22 (10): 3241-3249.
[28] Early Breast Cancer Trialists′Collaborative G (EBCTCG), Darby S, Mcgale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10, 801 women in 17 randomised trials [J]. Lancet, 2011, 378 (9804): 1707-1716.
[29] Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial [J]. Lancet, 1999, 353 (9165): 1641-1648.
[30] Early Breast Cancer Trialists′Collaborative G (EBCTCG), Mcgale P, Taylor C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials [J]. Lancet, 2014, 383 (9935): 2127-2135.
[31] Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies [J]. J Clin Oncol, 2006, 24 (15): 2268-2275.
[32] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会 (CSCO) 乳腺癌诊疗指南 (2020)[M]. 北京: 人民卫生出版社, 2020.
[33] Lu WL, Jansen L, Post WJ, et al. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis [J]. Breast Cancer Res Treat, 2009, 114 (3): 403-412.
[34] The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial [J]. JAMA 1994, 271 (20): 1587-1592.
[35] Rosselli Del Turco M, Palli D, Cariddi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer. a randomized trial. National Research Council Project on Breast Cancer follow-up [J]. JAMA, 1994, 271 (20): 1593-1597.
[36] Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial [J]. Lancet, 2010, 375 (9714): 563-571.
[37] Peters NH, Van Esser S, Van Den Bosch MA, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: The MONET-randomised controlled trial [J]. Eur J Cancer, 2011, 47 (6): 879-886.
[38] Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation [J]. N Engl J Med, 2002, 347 (8): 567-575.
[39] Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer [J]. N Engl
J Med, 2002, 347 (16): 1227-1232.
[40] Yu LX, Shi P, Tian XS, et al. A multi-center investigation of breast-conserving surgery based on data from the Chinese Society of Breast Surgery (CSBrS-005)[J]. Chin Med J (Engl), 2020, 133 (22): 2660-2664.
[41] Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection [J]. J Surg Oncol, 2010, 102 (2): 111-118.
[42] Ahmed S, Snelling A, Bains M, et al. Breast reconstruction [J]. Br Med J, 2005, 330 (7497): 943-948.
[43] Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [J]. J Clin Oncol, 26 (5): 778-785.
[44] Early Breast Cancer Trialists’Collaborative G (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J]. Lancet Oncol, 2018, 19 (1): 27-39.
[45] Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer [J]. Am J Roentgenol, 2005, 184 (3): 868-877.
[46] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet, 2014, 384 (9938): 164-172.
[47] Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes [J]. J Clin Oncol, 2012, 30 (15): 1796-1804.
[48] Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy [J]. N Engl J Med, 2017, 376 (22): 2147-2159.
[49] Von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J]. N Engl J Med, 2019, 380 (7): 617-628.
[50] Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [J]. Breast, 2003, 12 (5): 320-327.
[51] Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy [J]. J Clin Oncol, 25 (28): 4414-4422.
[52] Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases [J]. Eur J Cancer, 2014, 50 (2): 277-289.